- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06459635
Estudo de previsão de fase de dor de ataque de enxaqueca (PREDI-CRISIS)
Estudo de previsão da fase de dor das crises de enxaqueca em pacientes com enxaqueca episódica
The study of the ability to predict pain in a migraine attack, through premonitory symptoms and through an ambulatory monitoring device through real-time recording of hemodynamic variables, is one of the strategic lines of research of the unit. of Headaches at the Hospital de La Princesa since 2013 together with the Complutense and Polytechnic University of Madrid. Their results have been reflected in various publications (Pagán J, et al. Sensors 2015; Gago-Veiga AB, et al. J Pain Res 2018) and have promoted the creation of several invention patents.
Visão geral do estudo
Status
Descrição detalhada
Patients with episodic migraine will be recruited from the monographic headache clinics of the 7 centers participating in the study. These patients, for a maximum period of 2 months, must monitor their hemodynamic variables with a wearable device and record all the clinical characteristics of their migraine attacks. Subsequently, with these records, an individualized algorithm will be created for each patient that aims to predict the onset of the migraine attack.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Madrid
-
Madrid, Madrid, Espanha, 28006
- Hospital Universitario de La Princesa
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patients aged between 18 and 65 years with a diagnosis of episodic migraine who have between 4 and 14 days of headache per month. These patients will come from 7 Headache Units in Spain belonging to the following hospitals: • La Princesa University Hospital • Vall 'Hebron University Hospital • Marqués de Valdecilla University Hospital • Valladolid University Clinical Hospital • Donostia University Hospital • Lozano Blesa University Clinical Hospital • La Fe Polytechnic University Hospital
Descrição
Inclusion Criteria:
- Age between 15 years and 69 years.
- Diagnosed with migraine by a headache neurologist and according to the criteria proposed by ICHD-3.
- History of migraine of at least 1 year of evolution.
- Normal neurological examination.
- Have given your informed consent.
- Be able to describe your clinical situation and the characteristics of your headache.
- Have an average of 10 to 14 migraine days per month in the three months prior to inclusion (high-frequency episodic migraine).
- User-level management capacity of "smartphone" type electronic devices.
- Be able to complete two months of study follow-up.
Exclusion Criteria:
- Presence of another type of headache, with the exception of headache due to excessive use of analgesic medication.
- Cognitive deficiency or any other pathology that may prevent or make it difficult for the patient to perform the study correctly.
- Neurological focus in the examination.
- Pregnancy or breastfeeding period.
- Patients with known heart disease or bronchopathy, Sjögren's syndrome, diabetes mellitus, or hypo/hyperthyroidism.
- Carriers of pacemakers, neurostimulators or any other electronic device that is considered to make the interpretation of biometric records difficult.
- Anatomical problem that makes the use of the device impossible.
- Patients in whom it is expected that a change in migraine preventive treatment or other usual treatment will be possible during the study period.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: CASE_CONTROL
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Patients with episodic migraine
Patients with episodic migraine who present between 4 and 10 migraine attacks per month. These patients must have a diagnosis of migraine by a headache neurologist and according to the criteria proposed by ICHD-3. In addition, they must present at least 1 year of evolution of the migraine, as well as a normal neurological examination and have given their informed consent. |
|
Control patients
People who have never had a headache episode with migraine characteristics. These may present, at most, one episode per month of headache with non-migraine characteristics in the last 3 months. In turn, they should not have a family history of migraine (1st and 2nd degree). |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Development of a prediction strategy for the onset of migraine
Prazo: From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Develop a prediction strategy for the onset of migraine attacks in patients with episodic migraine, based on hemodynamic and clinical variables of migraine attacks. |
From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Posibility of predict the onset of pain in a migraine attack
Prazo: From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
To analyze whether it is possible to predict the onset of pain in a migraine attack, through ambulatory and non-invasive monitoring of physiological variables. |
From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
|
Individualized prediction algorithm
Prazo: From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Implement an individualized prediction algorithm that allows real-time prediction of the symptomatic phase of the migraine attack. |
From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
|
Effectiveness of the prediction model
Prazo: From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Measure the effectiveness of the prediction model both at the individual level and in a large group of patients. |
From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Ana Beatriz Gago Veiga, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Publicações e links úteis
Publicações Gerais
- Gago-Veiga AB, Pagan J, Henares K, Heredia P, Gonzalez-Garcia N, De Orbe MI, Ayala JL, Sobrado M, Vivancos J. To what extent are patients with migraine able to predict attacks? J Pain Res. 2018 Sep 27;11:2083-2094. doi: 10.2147/JPR.S175602. eCollection 2018.
- Pagan J, De Orbe MI, Gago A, Sobrado M, Risco-Martin JL, Mora JV, Moya JM, Ayala JL. Robust and Accurate Modeling Approaches for Migraine Per-Patient Prediction from Ambulatory Data. Sensors (Basel). 2015 Jun 30;15(7):15419-42. doi: 10.3390/s150715419.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 3513
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data (IPD) will not be shared with other researchers. This decision is based on data protection and confidentiality requirements in accordance with applicable European and national regulations (including GDPR). Given that this is a multicentre observational study conducted in routine clinical practice, access to IPD is restricted to the study investigators for the purposes of the predefined analyses.
Any potential secondary use of the dataset would only be considered in fully anonymized form and subject to prior ethical approval and compliance with applicable data protection legislation.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .